한글목차

종양 미세환경 시장은 2025년에는 18억 7,000만 달러로 추정되고, 2032년에는 43억 7,000만 달러에 이를 전망이며, 2025-2032년 연평균 성장률(CAGR) 12.9%로 성장이 예측되고 있습니다.

종양 미세환경은 다양한 세포성분과 비세포성분으로 구성된 복잡한 생태계이며, 서로 영향을 주면서 종양의 발생과 진행에 중요한 역할을 하고 있습니다. 이러한 구성 요소에는 면역세포, 섬유아세포, 혈관, 세포외 매트릭스, 신호전달 분자 등이 포함됩니다. 종양 미세환경을 이해하는 것은 암을 효과적으로 치료할 수 있는 표적 요법을 개발하기 위해 필수적입니다. 최근 종양 미세환경 연구는 종양세포와 그 주위 환경과의 역동적인 상호작용의 중요성을 인식하게 되어 큰 주목을 받고 있습니다. 종양 미세환경이 혈관신생, 면역반응, 전이, 약제내성 등 다양한 과정에 영향을 주는 것으로 밝혀졌습니다.

시장 역학 :

종양 미세환경 시장은 몇 가지 요인에 의해 향후 수년간 큰 성장이 전망될 것입니다. 주요 요인 중 하나는 세계 암 이환율의 증가입니다. 2020년 세계보건기구(WHO)에 따르면 암은 세계적으로 주요 사인 중 하나이며 매년 약 1,000만 명이 새로 발병하고 600만 명이 사망하고 있습니다. 이 때문에 암을 이해하고 치료하기 위한 선진적인 방법에 대한 수요가 높아져 시장 성장의 원동력이 되고 있습니다.

하지만 높은 연구개발 비용, 엄격한 규제 요건, 종양 미세환경 연구에서 동물 모델 사용과 관련된 윤리적 우려 등의 요인으로 인해 시장 성장이 억제될 수 있습니다. 게다가 숙련된 전문가가 한정되어 있는 것이나, 조사 수법이 표준화되어 있지 않은 것도, 시장 성장의 과제가 될 수 있습니다.

이러한 과제에도 불구하고, 종양 미세 환경 시장에는 큰 성장 기회가 있습니다. 다광자 현미경이나 인트라비탈 이미징 등의 이미징 기술의 진보에 의해, 연구자는 종양 미세환경을 실시간으로 고해상도로 조사할 수 있게 되었습니다. 게다가 개별화 의료의 출현과 정밀 종양학에 대한 주목의 고조는, 종양 미세환경에 관한 인사이트를 제공할 수 있는 바이오마커의 수요를 낳아, 시장 성장을 한층 더 촉진하고 있습니다.

게다가 시장 기업은 제휴 등의 무기적인 전략에 임하고 있어 이것이 예측 기간 중에 세계의 종양 미세환경 시장의 성장을 높일 것으로 예측됩니다. 예를 들어, 2023년 3월 20일 독일 바이오테크놀로지 기업인 바이오엔테크SE와 임상단계 바이오의약품 기업인 온코씨4, Inc.는 온코씨4의 차세대 항CTLA-4 모노클로날 항체 후보인 ONC-392를 다양한 암 적응증에서 단제요법 또는 병용요법으로 개발 및 상업화하기 위한 세계 독점적 라이선스 및 제휴 계약을 체결했다고 발표했습니다. CTLA-4는 다양한 기전으로 면역세포의 활성을 저해하는 분자입니다. OncoC4의 CTLA-4 항체 후보인 ONC-392는 종양 미세환경에서의 면역억제성 T세포(제어성 T세포, 'Tregs')를 제거하고, 정상조직에서의 Tregs를 온존하는 것을 목적으로 하고 있습니다.

본 조사의 주요 특징

• 본 보고서는 세계의 종양 미세환경 시장을 상세하게 분석하여 2024년을 기준연도로 하여 예측 기간(2025-2032년) 동안 시장 규모 및 복합연간 성장률(CAGR%)을 제공합니다.
• 또, 다양한 부문에 걸친 잠재적인 수익 기회를 해명해, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터에 근거해, 세계의 종양 미세환경 시장의 주요 기업 프로파일을 제공합니다.
• 본 보고서의 인사이트를 통해 마케팅 담당자 및 기업 경영진은 장래의 제품 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 세계의 종양 미세환경 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
• 이해관계자는 세계의 종양 미세환경 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적 및 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의 및 범위
• 주요 요약
• 일관된 기회 지도(COM)

제3장 시장 역학, 규제 및 동향 분석

• 시장 역학
  • 암 이환율 증가
  • 시약에 걸리는 고비용
  • AI와 머신러닝의 도입
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 출시 및 승인
• PEST 분석
• Porter's Five Forces 분석
• 합병 및 인수 시나리오

제4장 종양 미세환경 시장 : 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측 및 수요측 분석
• 경제에 미치는 영향

제5장 종양 미세환경 시장 : 암 유형별(2020-2032년)

• 폐암
• 대장암
• 유방암
• 전립선암
• 방광암
• 기타(흑색종, 신장암, 난소암 등)

제6장 종양 미세환경 시장 : 표적별(2020-2032년)

• T세포
• 종양 관련 대식세포
• 골수 유래 억제 세포
• 암 관련 섬유아세포
• 제어성 T 세포
• 기타(종양 관련 호중구, 수지상 세포 등)

제7장 종양 미세환경 시장 : 치료별(2020-2032년)

• 단일클론항체
• 사이토카인
• 암 백신
• 종양 용해성 바이러스
• 입양세포요법
• 기타(유전자 치료, 면역 조절제, 체크 포인트 억제제 등)

제8장 종양 미세환경 시장 : 최종 사용자별(2020-2032년)

• 바이오의약품기업
• 병원
• 진단실험실
• 연구기관
• CRO
• 기타(학술기관 등)

제9장 종양 미세환경 시장 : 지역별(2020-2032년)

• 북미
  • 미국
  • 캐나다
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 멕시코
  • 기타 라틴아메리카
• 유럽
  • 독일
  • 영국
  • 스페인
  • 프랑스
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 한국
  • ASEAN
  • 기타 아시아태평양
• 중동 및 아프리카
  • GCC 국가
  • 이스라엘
  • 남아프리카
  • 북아프리카
  • 중앙 아프리카
  • 기타 중동

제10장 경쟁 구도

• Thermo Fisher Scientific
• Illumina
• Danaher Corporation
• Merck KGaA
• BD Biosciences
• Promega Corporation
• Bio-Techne Corporation
• Bio-Rad Laboratories
• Hoffmann-La Roche Ltd
• QIAGEN NV
• Sartorius AG
• PerkinElmer
• Miltenyi Biotec
• Cell Signaling Technology
• BioLegend
• Abcam
• Takara Bio
• Fluidigm Corporation
• NanoString Technologies
• 10x Genomics
• Bethyl Laboratories

제11장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Tumor Microenvironment Market is estimated to be valued at USD 1.87 Bn in 2025 and is expected to reach USD 4.37 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.9% from 2025 to 2032.

The tumor microenvironment is a complex ecosystem consisting of various cellular and non-cellular components that interact with each other and play a crucial role in tumor development and progression. These components include immune cells, fibroblasts, blood vessels, the extracellular matrix, and signaling molecules. Understanding the tumor microenvironment is essential for developing targeted therapies that can effectively treat cancer. The study of the tumor microenvironment has gained significant attention in recent years, as researchers have realized the importance of this dynamic interaction between tumor cells and their surroundings. It is now evident that the tumor microenvironment can influence various processes, such as angiogenesis, immune response, metastasis, and drug resistance.

Market Dynamics:

The tumor microenvironment market is expected to witness significant growth in the coming years, driven by several factors. One of the major drivers is the increasing incidence of cancer worldwide. According to the World Health Organization (WHO), 2020, cancer is one of the leading causes of death globally, with approximately 10 million new cases and 6 million deaths reported annually. This has led to a substantial demand for advanced methods to understand and treat cancer, thereby driving market growth.

However, market growth can be restrained by factors, such as the high cost of research and development, stringent regulatory requirements, and ethical concerns related to the use of animal models in tumor microenvironment studies. Additionally, the limited availability of skilled professionals and the lack of standardization in research methodologies can pose challenges to market growth.

Despite these challenges, the tumor microenvironment market offers significant opportunities for growth. Technological advancements in imaging techniques, such as multiphoton microscopy and intravital imaging, have enabled researchers to study the tumor microenvironment in real-time and high resolution. Moreover, the emergence of personalized medicine and the increasing focus on precision oncology have created a demand for biomarkers that can provide insights into the tumor microenvironment, further driving market growth.

Moreover, market players are engaged in conducting inorganic strategies such as collaborations, and this is expected to increase the growth of the global tumor microenvironment market over the forecast period. For instance, on March 20, 2023, BioNTech SE, a German biotechnology company and OncoC4, Inc., a clinical-stage biopharmaceutical company, announced that they had entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. CTLA-4 is a molecule that inhibits the activity of immune cells via various mechanisms. OncoC4's CTLA-4 antibody candidate, ONC-392, aims to delete immunosuppressive T cells (regulatory T cells, "Tregs") in the tumor microenvironment but spare Tregs in healthy tissues.

Key features of the study:

• This report provides in-depth analysis of the global tumor microenvironment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global tumor microenvironment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Thermo Fisher Scientific, Illumina, Danaher Corporation, Merck KGaA , BD Biosciences, Promega Corporation, Bio-Techne Corporation , Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, QIAGEN N.V., Sartorius AG, PerkinElmer, Miltenyi Biotec, Cell Signaling Technology, BioLegend, Abcam, Takara Bio, Fluidigm Corporation, NanoString Technologies, 10x Genomics, and Bethyl Laboratories
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global tumor microenvironment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor microenvironment market

Detailed Segmentation:

• By Cancer Type
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
• By Target
  • T Cells
  • Tumor-Associated Macrophages
  • Myeloid-Derived Suppressor Cells
  • Cancer-Associated Fibroblasts
  • Regulatory T Cells
  • Others (Tumor-associated neutrophils, Dendritic cells etc.)
• By Therapy:
  • Monoclonal Antibodies
  • Cytokines
  • Cancer Vaccines
  • Oncolytic Viruses
  • Adoptive Cell Therapies
  • Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
• By End User:
  • Biopharmaceutical Companies
  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Contract Research Organizations (CROs)
  • Others (Academic Institutes and Others)
• By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Thermo Fisher Scientific
  • Illumina
  • Danaher Corporation
  • Merck KGaA
  • BD Biosciences
  • Promega Corporation
  • Bio-Techne Corporation
  • Bio-Rad Laboratories
  • F.Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • Sartorius AG
  • PerkinElmer
  • Miltenyi Biotec
  • Cell Signaling Technology
  • BioLegend
  • Abcam
  • Takara Bio
  • Fluidigm Corporation
  • NanoString Technologies
  • 10x Genomics
  • Bethyl Laboratories

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Tumor Microenvironment, By Cancer Type
  • Market Tumor Microenvironment, By Target
  • Market Tumor Microenvironment, By Therapy
  • Market Tumor Microenvironment, By End User
  • Market Tumor Microenvironment, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing cancer prevalence
  • High costs associated with reagents
  • Adoption of AI and machine learning
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Tumor Microenvironment Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Tumor Microenvironment Market , By Cancer Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Colorectal Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Breast Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Prostate Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Bladder Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Tumor Microenvironment Market , By Target, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• T Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Tumor-associated Macrophages
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Myeloid-Derived Suppressor Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cancer-Associated Fibroblasts
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Regulatory T Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others (Tumor-associated neutrophils, Dendritic cells etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Tumor Microenvironment Market , By Therapy, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cytokines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cancer Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Oncolytic Viruses
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Adoptive Cell Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Tumor Microenvironment Market , By End User, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Biopharmaceutical Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Contract Research Organizations (CROs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Others (Academic Institutes and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Tumor Microenvironment Market , By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • GCC Countries
    • Israel
    • South Africa
    • North Africa
    • Central Africa
    • Rest of Middle East

10. Competitive Landscape

• Thermo Fisher Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Illumina
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Danaher Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• BD Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Promega Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bio-Techne Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bio-Rad Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• QIAGEN N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sartorius AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• PerkinElmer
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Miltenyi Biotec
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Cell Signaling Technology
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• BioLegend
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Abcam
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Takara Bio
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Fluidigm Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• NanoString Technologies
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• 10x Genomics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bethyl Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

11. Section

• Research Methodology
• About us